| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | 0.067 | 0.02 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.02 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | JNJ-26854165 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.078 | 0.02 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.12 | 0.03 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.03 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.03 |